"Because it has been shown that ADAM10/17 influence many mediators of CKD-induced atherosclerosis, it would be very interesting to dive into the detailed mechanisms of action, as these so far remain rather elusive. This is crucial as, currently, treatment options to reduce CV mortality in patients with CKD are very limited, and clinical trials designed to reduce CV mortality in CKD patients have not proven to be successful yet."